Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLS-6150 Safety and Immunogenicity in Healthy and HCV-Cured Adults
NCT03674125Phase 1Completed
- Sponsor
- GeneOne Life Science, Inc.
- Start
- Sep 2018
- Primary completion
- Apr 2020
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of INO-8000 in hepatitis C (HCV) (4 arms), sponsored by GeneOne Life Science, Inc. Primary endpoints: Incidence of adverse events, Administration (injection) site reactions and 1 more. Started Sep 2018; status: completed.
02
Drugs
INO-8000
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03674125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674125.